ArticleMolecular cancer2007
Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma.
Article in Molecular cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Methylation and molecular profiles of ependymoma: Influence of patient age and tumor anatomic location.Molecular and clinical oncology · 2021Article
- A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB.Cell reports · 2018Article
- Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.Molecular neurobiology · 2017Review
- Supratentorial "vascular" variant of ependymoma: a lesser known morphologic variant and a diagnostic pitfall.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016Article
- Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling.Neuro-oncology · 2016Article
- Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression.Journal of neuro-oncology · 2013Article
- Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.Acta neuropathologica · 2012Article
- Clear cell ependymoma with trisomy 19 developing bone metastases.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- Targets for therapy in ependymoma.Targeted oncology · 2011Review
- Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts.Journal of negative results in biomedicine · 2011Article
- Cross-species genomics matches driver mutations and cell compartments to model ependymoma.Nature · 2010Article
- Intracranial ependymoma associated with multiple endocrine neoplasia type 1.Journal of endocrinological investigation · 2010Article
- Article
- Classification and controversies in pathology of ependymomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2009Review
- Chordoid glioma: a case report and molecular characterization of five cases.Brain pathology (Zurich, Switzerland) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors. They vary in regard to their age at first symptom, localization, morphology and prognosis. Genetic data also suggests heterogeneity. We define a newly recognized subset of ependymal tumors, the trisomy 19 ependymoma. Histologically, they are compact lesions characterized by a rich branched capillary network amongst which tumoral cells are regularly distributed. When containing clear cells they are called clear cell ependymoma. Most trisomy 19 ependymomas are supratentorial WHO grade III tumors of the young. Genetically, they are associated with trisomy 19, and frequently with a deletion of 13q21.31-31.2, three copies of 11q13.3-13.4, and/or deletions on chromosome 9. These altered chromosomal regions are indicative of genes and pathways involved in trisomy 19 ependymoma tumorigenesis. Recognition of this genetico-histological entity allows better understanding and dissection of ependymal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.